Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis.
Fernando Caravaca-FontánKate I StevensMaite PadrónAna HuertaMarco MontomoliJuan VillaFayna GonzálezCristina VegaManuel López MendozaLoreto FernándezAmir ShabakaAntolina Rodríguez-MorenoAdoración Martín-GómezPedro J LabradorAlicia Molina AndújarM Carmen Prados SolerLuis Martín-PenagosEstefanía YeroviLaura Medina ZahoneroJosé Carlos De La FlorCarmen MonMeritxell IbernonAstrid Rodríguez GómezRosa MiquelMilagros SierraVictoria MascarósLeonella LuzardoMarios PapasotiriouDavid ArroyoÚrsula VerdallesPatricia Martínez-MiguelGonzalo Ramírez-GuerreroSaúl Pampa-SaicoEsperanza Moral BerrioJosé Luis Pérez CangaBlanca TarragónPilar Fraile GómezDabaiba RegidorJavier ReleaMarc XipellCristina Andrades GómezMaruja NavarroÁlvaro ÁlvarezBegoña RivasLuis F QuintanaEduardo GutiérrezMiguel Ángel Pérez-ValdiviaBalazs OdlerAndreas KronbichlerColin G GeddesHans-Joachim AndersJürgen FloegeGema Fernández-JuárezManuel Praganull nullPublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023)
The use of SGLT2i was associated with a significant reduction of proteinuria. This percentage change is greater in patients with higher BMI. Higher serum albumin at SGLT2i onset is associated with higher probability of achieving a ≥ 30% proteinuria reduction.
Keyphrases